Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

British Journal of Haematology

Volumn 133, Issue 1, 2006, Pages 83-92

  Ge, Yun ^a   Zhan, Fenghuang ^a   Barlogie, Bart ^a   Epstein, Joshua ^a   Shaughnessy Jr , John ^a   Yaccoby, Shmuel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone marrow; Fibroblast activation protein; Mesenchymal stem cells; Microenvironment; Myeloma; Osteoclasts

Indexed keywords

SEPRASE; SMALL INTERFERING RNA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TUMOR; CELL INTERACTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCID MOUSE; STROMA; UPREGULATION;

ADIPOCYTES; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOCLASTS; PLASMA CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33644644120     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.05976.x     Document Type: Article

References (48)

1. Abe M. Hiura K. Wilde J. Shioyasono A. Moriyama K. Hashimoto T. Kido S. Oshima T. Shibata H. Ozaki S. Inoue D. Matsumoto T. 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood 104 2484 2491
2. Adams S. Miller G.T. Jesson M.I. Watanabe T. Jones B. Wallner B.P. 2004 PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism Cancer Research 64 5471 5480
3. Anderson K.C. Shaughnessy Jr. J.D. Barlogie B. Harousseau J.L. Roodman G.D. 2002 Multiple myeloma Hematology (American Society of Hematology. Educational Program) 214 240
4. Bataille R. Chappard D. Marcelli C. Dessauw P. Baldet P. Sany J. Alexandre C. 1991 Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma Journal of Clinical Investigation 88 62 66
5. Chen W.T. Kelly T. Ghersi G. 2003 DPPIV, seprase, and related serine peptidases in multiple cellular functions Current Topic in Developmental Biology 54 207 232
6. Cheng J.D. Weiner L.M. 2003 Tumors and their microenvironments: tilling the soil Commentary re: A. M. Scott et al, A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical Cancer Research, 9, 1639-1647, 2003 Clinical Cancer Research 9 1590 1595
7. Cheng J.D. Dunbrack Jr. R.L. Valianou M. Rogatko A. Alpaugh R.K. Weiner L.M. 2002 Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model Cancer Research 62 4767 4772
8. Croucher P.I. De Hendrik R. Perry M.J. Hijzen A. Shipman C.M. Lippitt J. Green J. Van Marck E. Van Camp B. Vanderkerken K. 2003 Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival Journal of Bone and Mineral Research 18 482 492
9. Dalton W.S. 2003 The tumor microenvironment: focus on myeloma Cancer Treatment Reviews 29 Suppl. 1 11 19
10. Epstein J. Yaccoby S. 2003 Consequences of interactions between the bone marrow stroma and myeloma Hematology Journal 4 310 314
11. Garin-Chesa P. Old L.J. Rettig W.J. 1990 Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proceedings of the National Academy of Sciences United States of America 87 7235 7239
12. Ghersi G. Dong H. Goldstein L.A. Yeh Y. Hakkinen L. Larjava H.S. Chen W.T. 2002 Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex Journal of Biological Chemistry 277 29231 29241
13. Grigorieva I. Thomas X. Epstein J. 1998 The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone Experimental Hematology 26 597 603
14. Huang Y. Wang S. Kelly T. 2004 Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer Cancer Research 64 2712 2716
15. Huber M.A. Kraut N. Park J.E. Schubert R.D. Rettig W.J. Peter R.U. Garin-Chesa P. 2003 Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors Journal of Investigative Dermatology 120 182 188
16. Kelly T. 2005 Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy Drug Resistance Updates 8 51 58
17. Mueller S.C. Ghersi G. Akiyama S.K. Sang Q.X. Howard L. Pineiro-Sanchez M. Nakahara H. Yeh Y. Chen W.T. 1999 A novel protease-docking function of integrin at invadopodia Journal of Biological Chemistry 274 24947 24952
18. Muller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Barrera J.L. Mohar A. Verastegui E. Zlotnik A. 2001 Involvement of chemokine receptors in breast cancer metastasis Nature 410 50 56
19. Mundy G.R. 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nature Reviews Cancer 2 584 593
20. O'Keefe R.J. Guise T.A. 2003 Molecular mechanisms of bone metastasis and therapeutic implications Clinical Orthopaedics 415 Suppl. S100 S104
21. Park J.E. Lenter M.C. Zimmermann R.N. Garin-Chesa P. Old L.J. Rettig W.J. 1999 Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts Journal of Biological Chemistry 274 36505 36512
22. Pearse R.N. Sordillo E.M. Yaccoby S. Wong B.R. Liau D.F. Colman N. Michaeli J. Epstein J. Choi Y. 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proceedings of the National Academy of Sciences United States of America 98 11581 11586
23. Phillips R.J. Burdick M.D. Lutz M. Belperio J.A. Keane M.P. Strieter R.M. 2003 The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases American Journal of Respiratory and Critical Care Medicine 167 1676 1686
24. Ramirez-Montagut T. Blachere N.E. Sviderskaya E.V. Bennett D.C. Rettig W.J. Garin-Chesa P. Houghton A.N. 2004 FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor Oncogene 23 5435 5446
25. Rash-Yahana M. Pikarsky E. Abramovitch R. Zeira E. Pal B. Karplus R. Beider K. Avniel S. Kasem S. Galun E. Peled A. 2004 Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis FASEB Journal 18 1240 1242
26. Rettig W.J. Garin-Chesa P. Beresford H.R. Oettgen H.F. Melamed M.R. Old L.J. 1988 Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells Proceedings of the National Academy of Sciences United States of America 85 3110 3114
27. Rettig W.J. Garin-Chesa P. Healey J.H. Su S.L. Ozer H.L. Schwab M. Albino A.P. Old L.J. 1993 Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin Cancer Research 53 3327 3335
28. Roodman G.D. 2002 Role of the bone marrow microenvironment in multiple myeloma Journal of Bone and Mineral Research 17 1921 1925
29. Roodman G.D. 2004a Pathogenesis of myeloma bone disease Blood Cells Molecules and Diseases 32 290 292
30. Roodman G.D. 2004b Mechanisms of bone metastasis North England Journal of Medicine 350 1655 1664
31. Scott A.M. Wiseman G. Welt S. Adjei A. Lee F.T. Hopkins W. Divgi C.R. Hanson L.H. Mitchell P. Gansen D.N. Larson S.M. Ingle J.N. Hoffman E.W. Tanswell P. Ritter G. Cohen L.S. Bette P. Arvay L. Amelsberg A. Vlock D. Rettig W.J. Old L.J. 2003 A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer Clinical Cancer Research 9 1639 1647
32. Silvestris F. Cafforio P. Tucci M. Grinello D. Dammacco F. 2003 Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease British Journal of Haematology 122 39 52
33. Sun L. Adebanjo O.A. Moonga B.S. Corisdeo S. Anandatheerthavarada H.K. Biswas G. Arakawa T. Hakeda Y. Koval A. Sodam B. Bevis P.J. Moser A.J. Lai F.A. Epstein S. Troen B.R. Kumegawa M. Zaidi M. 1999 CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption Journal of Cell Biology 146 1161 1172
34. Taichman R.S. Cooper C. Keller E.T. Pienta K.J. Taichman N.S. McCauley L.K. 2002 Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone Cancer Research 62 1832 1837
35. Tian E. Zhan F. Walker R. Rasmussen E. Ma Y. Barlogie B. Shaughnessy J.D. 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma New England Journal of Medicine 349 2483 2494
36. Tusher V.G. Tibshirani R. Chu G. 2001 Significance analysis of microarrays applied to the ionizing radiation response Proceedings of the National Academy of Sciences USA 98 5116 5121
37. Vanderkerken K. De Leenheer E. Shipman C. Asosingh K. Willems A. Van Camp B. Croucher P. 2003 Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma Cancer Research 63 287 289
38. Vlasveld L.T. 2003 Low cobalamin (vitamin B12) levels in multiple myeloma: a retrospective study Netherlands Journal of Medicine 61 249 252
39. Yaccoby S. 2005 The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype Clinical Cancer Research 11 7599 7606
40. Yaccoby S. Epstein J. 1999 The proliferative potential of myeloma plasma cells manifest in the SCID-hu host Blood 94 3576 3582
41. Yaccoby S. Barlogie B. Epstein J. 1998 Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations Blood 92 2908 2913
42. Yaccoby S. Pearse R.N. Johnson C.L. Barlogie B. Choi Y. Epstein J. 2002a Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity British Journal of Haematology 116 278 290
43. Yaccoby S. Johnson C.L. Mahaffey S.C. Wezeman M.J. Barlogie B. Epstein J. 2002b Antimyeloma efficacy of thalidomide in the SCID-hu model Blood 100 4162 4168
44. Yaccoby S. Wezeman M.J. Henderson A. Cottler-Fox M. Yi Q. Barlogie B. Epstein J. 2004 Cancer and the microenvironment: myeloma-osteoclast interactions as a model Cancer Research 64 2016 2023
45. Yaccoby S. Wezeman M.J. Zangari M. Walker R. Cottler-Fox M. Gaddy D. Ling W. Saha R. Barlogie B. Tricot G. Epstein J. 2006 Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems andmyelomatous SCID-hu mice Haematologica 91 53 60
46. Zhan F. Hardin J. Kordsmeier B. Bumm K. Zheng M. Tian E. Sanderson R. Yang Y. Wilson C. Zangari M. Anaissie E. Morris C. Muwalla F. van Rhee F. Fassas A. Crowley J. Tricot G. Barlogie B. Shaughnessy J. 2002 Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood 99 1745 1757
47. Zhan F. Barlogie B. Shaughnessy J. 2003a Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling Seminars in Hematology 40 308 320
48. Zhan F. Tian E. Bumm K. Smith R. Barlogie B. Shaughnessy J. 2003b Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development Blood 101 1128 1140